氟贝他吡[18F](Florbetapir F-18) - 药物靶点：APP_在研适应症：阿尔茨海默症，造影剂_专利_临床

概要

基本信息

药物类型

小分子化药、诊断用放射药物

别名

18F-AV-45、4-{(E)-2-[6-(2-{2-[2-(18F)fluoroethoxy]ethoxy}ethoxy)pyridin-3-yl]ethenyl}-N-methylaniline、[18F]Florbetapir

+ [18]

靶点

APP

作用方式

调节剂、增强剂

作用机制

APP调节剂(β-淀粉状蛋白A4调节剂)、PET imaging(正电子发射断层成像术增强剂)

治疗领域

神经系统疾病其他疾病

在研适应症

阿尔茨海默症造影剂

非在研适应症

慢性创伤性脑病认知功能障碍阿尔茨海默病引起的痴呆症+ [5]

原研机构

Eli Lilly & Co.

在研机构

PDRadiopharma, Inc.

Avid Radiopharmaceuticals, Inc.Eli Lilly Nederland BV

+ [1]

非在研机构

南京江原安迪科正电子研究发展有限公司

Eli Lilly & Co.

权益机构

Eli Lilly & Co.

King Faisal Specialist Hospital & Research Centre

最高研发阶段批准上市

首次获批日期

美国 (2012-04-06),

造影剂

最高研发阶段(中国)无进展

特殊审评-

登录后查看时间轴

结构/序列

分子式C20H25FN2O3

InChIKeyYNDIAUKFXKEXSV-CRYLGTRXSA-N

CAS号956103-76-7

关联

81

项与氟贝他吡[18F] 相关的临床试验

NCT06600880

/ Not yet recruiting临床1期IIT

Neuronavigation-guided Focused Ultrasound-induced Blood-brain Barrier Opening in Alzheimer's Disease Patients and Its Effects on Brain Amyloid and Tau

The primary purpose of this phase 1b study is to further assess the safety and reversibility of focused ultrasound induced blood-brain barrier opening (FUS-BBBO) in participants with Alzheimer´s Disease (AD) using a single-element transducer with neuronavigation guidance. Preliminary results from our phase 1a study demonstrate that our neuronavigation-guided FUS system was capable of safely and transiently open the BBB in participants with AD. The information collected in this new study may be used to design future clinical trials to ultimately provide a viable alternative for treatment of AD in a safe and noninvasive manner.
Our secondary objective includes the assessment of the therapeutic efficacy of FUS-BBBO in reducing amyloid beta and neurofibrillary tangles, the main hallmark pathologies of AD, using PET tracers. Based on our preclinical studies in AD transgenic mouse models, FUS-BBBO alone was able to reduce both the amyloid beta and tau protein load, resulting in improvements in behavioral tasks assessing memory. Therefore, in this new study, the effect of FUS-BBBO on the amyloid beta and tau protein load in patients with AD will be assessed through the use of PET tracers.

开始日期2026-08-01

申办/合作机构-

NCT06790394

/ Not yet recruiting临床1期

A Test-retest Study to Evaluate the Reproducibility of [18F]Florbetaben PET Imaging in Patients With Cardiac Amyloidosis and Control Patients

This study is an open-label study to evaluate and characterize test-retest reliability of [18F]florbetaben PET in subjects with AL-CA and ATTR-CA compared to non-CA subjects. Quantification of the [18F]florbetaben parameters related to the deposition of amyloid in the heart (such as Myocardial Tracer Retention (MTR) or Retention Index (RI)), and the variability in these parameters after repeated imaging will be evaluated. Measurement of blood metabolites and comparison of invasive with non-invasive quantification of [18F]florbetaben uptake in the heart will be performed.

开始日期2025-10-01

申办/合作机构

Life Molecular Imaging Ltd.

[+1]

NCT07012993

/ Recruiting临床2期IIT

Evaluation of Ultralow Dose PET Imaging for Detecting Amyloid Tracer Uptake

The goal of this clinical trial is to evaluate an investigational ultralow dose PET imaging technique for Alzheimer's disease, mild cognitive impairment, other forms of dementia detection and monitoring. The main question it aims to answer is:
Can the investigators optimize the timing, scan duration, and image reconstruction to reduce the radiation dose 10-100 fold of the current clinical standard? Participants will be injected with a radioactive tracer called 18F-Florbetapir or 18F-Flutemetamol and be imaged on a new type of high-sensitivity PET scanner for up to 3 hours

开始日期2025-05-20

申办/合作机构

Nuclear Energy Institute

100 项与氟贝他吡[18F] 相关的临床结果

登录后查看更多信息

100 项与氟贝他吡[18F] 相关的转化医学

登录后查看更多信息

100 项与氟贝他吡[18F] 相关的专利（医药）

登录后查看更多信息

384

项与氟贝他吡[18F] 相关的文献（医药）

2025-10-01·European Journal of Nuclear Medicine and Molecular Imaging

Evaluating gray matter heterotopia with Florbetapir and Flortaucipir pet: a case report

Article

作者: Shu, Qiaoqiao ; Xu, Zhenchun ; Xiang, Xiaojiao ; Cai, Liang ; Feng, Yue

2025-09-01·Alzheimers & Dementia

Birth weight, incident dementia risk, and PET amyloid burden: The ARIC study

Article

作者: Emanuel, Olivia M. ; Egle, Marco ; Groechel, Renée C. ; Lee, Mark ; Sullivan, Kevin J. ; Wong, Dean F. ; Gottesman, Rebecca F. ; Lutsey, Pamela L. ; Schneider, Andrea L. C. ; Mosley, Thomas H.

Abstract:

INTRODUCTION:

The relationships among birth weight (BW), incident dementia, and amyloid beta (Aβ) are unknown.

METHODS:

Ten thousand four hundred seventy‐six Atherosclerosis Risk in Communities (ARIC) study participants without dementia reported their BW (1996–1998; low [< 5.5 lbs], medium [5.5–9.0 lbs], or high [> 9.0 lbs]), if premature (yes/no), and were followed for incident dementia (N dementia = 2550) through 2019. A subset (N = 312) had florbetapir positron emission tomography (2011–2014). BW was evaluated in association with dementia (Cox proportional hazards) and Aβ (logistic regression), adjusted for demographics, apolipoprotein E ε4, and vascular risk. Effect modification by race was explored.

RESULTS:

Neither low BW nor prematurity were associated with dementia. Dementia risk was elevated in Black (adjusted hazard ratio 1.95, 95% confidence interval 1.33, 2.86) but not White participants reporting high (versus medium) BW (P‐interaction = 0.001). BW was not associated with Aβ.

DISCUSSION:

Low BW was not associated with dementia or Aβ. High BW was associated with dementia in Black participants only. Further research should evaluate the role of BW in dementia etiology.

Highlights:

Low birth weight was not associated with an increased risk of incident dementia.The association between birth weight and incident dementia was modified by race.High birth weight was associated with dementia in Black adults.Odds of elevated standardized uptake value ratio was lower for those who were low birth weight.

2025-05-04·Journal of Sulfur Chemistry

Small molecule heterocycles: design and synthesis of novel fluorescent Benzothiazoles for early detection of Alzheimer’s disease

作者: Sharma, Vijay ; Sundaram, G.S.M.

Diagnostic agents capable of imaging β-amyloid (Aβ) plaques at prodromal stages could provide noninvasive tools to assess plaque burden and assist in determining efficacy of disease-modifying therapeutic interventions in vivo.To accomplish this goal, FDA approved 18F-incorporated tracers, such as Florbetapir, Flutemetamol, and Florbetaben may allow quant. anal. of therapeutic efficacy of disease-modifying treatments that attenuate Aβ pathophysiol. in vivo.Although promising, these tracers show high off-target binding.Importantly, current anti-amyloid therapy also targets diffuse amyloid plaques (included in revised NIAAA criteria for detecting AD) and other forms of amyloid plaques.Therefore, mols. capable of detecting both diffuse and fibrillar plaque pathol. can potentially offer better quant. tools for interrogating efficacy of anti-amyloid therapy.To achieve this goal, herein, we report synthesis and characterization of new small organic mols.: ((Z,E)-4-(2-(6-(2-Fluoroethoxy)benzo[d]thiazol-2-yl)vinyl)-N,N-dimethylaniline), ((Z)-4-(2-(6-(2-(2-(3-Fluoropropoxy)ethoxy)ethoxy)benzo[d]thiazol-2-yl)vinyl)-N,N-dimethylaniline) and ((E)-4-(2-(6-(2-(2-(3-Fluoropropoxy)ethoxy)ethoxy)benzo[d]thiazol-2-yl)vinyl)-N,N-dimethylaniline) We also report preliminary investigations on binding affinity in vitro.While demonstrated a relatively higher affinity, both and showed moderate affinity for Aβ1-42 aggregates in vitro.Furthermore, all 3 agents showed ability to detect Aβ fibrillar and diffuse plaque pathol. in brain sections of APP/PS1 transgenic mice and post-mortem confirmed AD human brain tissue sections.

77

项与氟贝他吡[18F] 相关的新闻（医药）

2025-10-07

·FierceBiotech

Lilly calls for \'urgent improvements\' in Europe to boost diagnostic testing for Alzheimer\'s

Eli Lilly says Alzheimer\'s disease experts are warning the disease “remains critically underdiagnosed\" across Europe. \n Eli Lilly is calling on European countries to make “urgent improvements” to their Alzheimer’s disease diagnostic testing practices just weeks after nabbing a new approval on the continent for its Alzheimer\'s therapy Kisunla.The Indianapolis Big Pharma has teamed up with leading Alzheimer\'s experts at this year\'s Alzheimer Europe Conference to call for “urgent improvements to diagnostic pathways to ensure people in Europe can benefit from new therapeutic innovation.”Lilly points to a recent survey, published in the Journal of Alzheimer’s Disease, that found 70% of clinicians believe biomarker tests, which can find evidence of Alzheimer\'s or dementia, are “important or extremely important.\" Still, such tests remain \"underutilized,\" according to Lilly\'s Oct. 7 release.The survey questioned clinicians who treat patients with mild cognitive impairment (MCI) and Alzheimer\'s in France, Germany, Italy, Spain, the U.K., Japan and the U.S. The team found that across these countries, fewer than 1 in 5 patients (15.2%) received biomarker testing to confirm the specific pathology, with those in Germany and the U.K. the least likely to receive these tests, according to the journal.As a result, experts warn Alzheimer\'s and dementia “remain critically underdiagnosed,” Lilly said in the release, which has the effect of \"denying patients the opportunity to access treatment and care options.\"Lilly markets Kisunla, which works as an amyloid-plaque-targeting therapy and has an FDA approval for early symptomatic Alzheimer\'s, which includes the MCI or the mild dementia stages of the disease.The drug was approved by the FDA last year and received a final European sign-off just last month.To qualify for the drugs, patients must have a confirmed amyloid pathology, which can be done via several routes including a PET scan, a blood test or an MRI.Lilly also markets Amyvid, which works as an injectable prescription imaging agent to find high level of plaques. These are a buildup of a protein called amyloid beta in the brain that, if found, can be ultimately used by patients or their doctors to help prescribe Alzheimer\'s meds such as Kisunla. More diagnoses of Alzheimer\'s also mean potentially more uptake for medicines. Rival drug Leqembi, marketed by Biogen and Eisai, was also approved in the EU earlier this year.“Emerging therapies that target the pathology of Alzheimer\'s disease offer hope to slow progression and delay the need for care services,” said Stéphane Epelbaum, M.D., Ph.D., associate vice president for international medical affairs at Eli Lilly, in a statement.“But this possibility hinges on early detection, as approximately one-third of individuals in early symptomatic stages of the disease will progress to more advanced clinical stages within one year. Timely and accurate diagnosis is essential to ensure patients can access the next generation of Alzheimer\'s disease care.”

$Lilly calls for \'urgent improvements\' in Europe to boost diagnostic testing for Alzheimer\'s$

上市批准

2025-08-30

·PRNewswire

FDA Approval of Leqembi Subcutaneous Formulation Charts Path to Combination Therapies for Alzheimer's Disease

Subcutaneous delivery increases accessibility and introduces potential for at-home administration, following model of diabetes and GLP-1 drugs NEW YORK, Aug. 29, 2025 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) today announced its approval of a subcutaneous formulation of Leqembi (lecanemab), branded as Leqembi Iqlik, for weekly maintenance dosing following the 18-month IV initiation phase. This is a major advancement that opens the door for faster and simpler drug delivery and paves the way for combination therapies – the same strategy that revolutionized cancer care. "This shift to subcutaneous maintenance dosing is a crucial step toward making Leqembi more accessible for patients, similar to how diabetes and GLP-1 medications are delivered, and represents the first step towards the day when patients can bypass infusions altogether," said Dr. Howard Fillit, Co-Founder and Chief Science Officer at the ADDF. "This milestone lessens the burden on patients and caregivers by reducing the logistical challenges of receiving Alzheimer's treatment, while also bringing us closer to the day when patients can more easily receive a combination of drugs, potentially administered from home." Subcutaneous delivery means the drug can be injected just under the skin using an autoinjector once a week – taking only about 15 seconds – rather than requiring hour-long intravenous infusions in hospitals or infusion sites. While this administration method is currently only approved for maintenance dosing, Eisai and Biogen plan to file another application next week for subcutaneous dosing without the need for an IV initiation phase. As more Alzheimer's treatments progress through development and gain approval, subcutaneous formulations will likely become increasingly common. Beyond convenience, this delivery innovation removes a critical barrier to combination therapies. With a more practical and scalable approach to drug administration, physicians will be better positioned to incorporate additional therapies that target the full spectrum of aging biology. This is especially timely as more than 70% of the current Alzheimer's drug pipeline focuses on non-amyloid pathways. "We've long known that Alzheimer's is not a one-target disease, and the future lies in precision combination therapies tailored to each patient based on their individual biomarker profiles," Dr. Fillit said. "Subcutaneous delivery is more than an upgrade – it's a gateway to the next generation of Alzheimer's care, accelerating our ability to bring effective, multi-modal treatment regimens to the millions of patients who need them." About The Alzheimer's Drug Discovery Foundation (ADDF) Founded in 1998 by Leonard A. and Ronald S. Lauder, the Alzheimer's Drug Discovery Foundation is dedicated to rapidly accelerating the development of drugs to prevent, treat, and cure Alzheimer's disease. The ADDF is the only public charity solely focused on funding the development of drugs for Alzheimer's, employing a venture philanthropy model to support research in academia and the biotech industry. The ADDF's leadership and contributions to the field have played a pivotal role in bringing the first Alzheimer's PET scan (Amyvid®) and blood test (PrecivityAD®) to market, as well as fueling the current robust and diverse drug pipeline. Through the generosity of its donors, the ADDF has awarded more than $370 million to fund 765 Alzheimer's drug development, biomarker, and prevention programs in 21 countries. To learn more, please visit: . SOURCE Alzheimer's Drug Discovery Foundation WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

上市批准

2025-07-28

·PRNewswire

Next Era of Alzheimer's Care Will be Defined by Precision Prevention

New U.S. study reflects growing role of lifestyle interventions, further highlighting need to study lifestyle and drugs in combination NEW YORK, July 28, 2025 /PRNewswire/ -- Results from the U.S. Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk (U.S. POINTER) released today strengthen the case for precision prevention, a strategy set to revolutionize Alzheimer's care by combining lifestyle changes with targeted therapeutics based on individual risk factors. "The future lies in precision prevention," said Dr. Howard Fillit, Co-Founder and Chief Science Officer of the Alzheimer's Drug Discovery Foundation. "We have seen this model succeed in cancer and heart disease, and with a growing body of evidence showing neither lifestyle nor drugs can stop Alzheimer's alone, now is the time to double down on studying the two in combination, which will lay the path for precision medicine." The ADDF is driving a new era of clinical trials that look at lifestyle and therapeutic interventions in tandem, including Dr. Miia Kivipelto's MET-FINGER study, which has created a blueprint for combination therapy studies going forward. The U.S. POINTER study, released during the Alzheimer's Association International Conference (AAIC) and published simultaneously in the Journal of the American Medical Association (JAMA), found multidomain lifestyle interventions supported cognitive health in aging populations. This builds on previous findings from Dr. Miia Kivipelto's original FINGER trial, the first to show the critical role of lifestyle changes in preventing dementia. U.S. POINTER showed its structured high-intensity lifestyle interventions benefitted participants regardless of their APOE4 carrier status, a genetic risk factor for Alzheimer's disease. This contrasts findings from the FINGER study, which showed benefit especially in carriers of APOE4, and further highlights the wide-reaching impacts of lifestyle changes. "The U.S. POINTER results validate the findings of the FINGER study in a more diverse U.S. population," said Dr. Kivipelto. "This is yet another proof point that lifestyle can have a tremendous impact on the brain. By developing personalized scientific approaches to match each patient's unique biomarker profile with a combined drug and prevention plan, we are redefining how we treat and prevent Alzheimer's." About The Alzheimer's Drug Discovery Foundation (ADDF) Founded in 1998 by Leonard A. and Ronald S. Lauder, the Alzheimer's Drug Discovery Foundation is dedicated to rapidly accelerating the development of drugs to prevent, treat, and cure Alzheimer's disease. The ADDF is the only public charity solely focused on funding the development of drugs for Alzheimer's, employing a venture philanthropy model to support research in academia and the biotech industry. The ADDF's leadership and contributions to the field have played a pivotal role in bringing the first Alzheimer's PET scan (Amyvid®) and blood test (PrecivityAD®) to market, as well as fueling the current robust and diverse drug pipeline. Through the generosity of its donors, the ADDF has awarded more than $370 million to fund 765 Alzheimer's drug development, biomarker, and prevention programs in 21 countries. To learn more, please visit: . SOURCE Alzheimer's Drug Discovery Foundation WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床研究

100 项与氟贝他吡[18F] 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D09617	氟贝他吡[18F]	V09AX05	DB09149

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
阿尔茨海默症	欧盟	Eli Lilly Nederland BV	2013-01-14
阿尔茨海默症	冰岛	Eli Lilly Nederland BV	2013-01-14
阿尔茨海默症	列支敦士登	Eli Lilly Nederland BV	2013-01-14
阿尔茨海默症	挪威	Eli Lilly Nederland BV	2013-01-14
造影剂	美国	Avid Radiopharmaceuticals, Inc.	2012-04-06

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
阿尔茨海默病引起的痴呆症	临床3期	中国	南京江原安迪科正电子研究发展有限公司	2022-10-20
认知功能障碍	临床3期	美国	Avid Radiopharmaceuticals, Inc.	2011-07-01
轻度认知障碍	临床3期	-	Avid Radiopharmaceuticals, Inc.	2011-02-01
慢性创伤性脑病	临床2期	美国	Avid Radiopharmaceuticals, Inc.	2014-06-01
路易体病	临床2期	美国	Avid Radiopharmaceuticals, Inc.	2010-03-01
纹状体黑质变性	临床2期	美国	Avid Radiopharmaceuticals, Inc.	2010-03-01
额颞痴呆	临床2期	英国	Avid Radiopharmaceuticals, Inc.	2009-09-01
帕金森病	临床2期	美国	Avid Radiopharmaceuticals, Inc.	2009-01-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04118764 (CTgov)	N/A	阿尔茨海默症	6	Neuronavigation-guided single-element focused ultrasound transducer+Amyvid+Definity	範網願廠鹽製顧夢廠繭 = 觸獵積構範餘淵鬱鑰築膚獵遞糧鑰顧積齋顧膚 (廠網廠範築夢鬱範鹹醖, 選獵夢顧範餘構鏇廠壓 ~ 顧艱蓋淵壓遞艱糧夢襯) 更多	-	2024-08-26
NCT01683825 (CTgov)	临床4期	老年性心脏淀粉样变性	23	florbetapir	鏇網築艱遞齋製膚鑰窪(鹽簾衊艱構醖衊繭製鹹) = 鑰選鏇齋構醖選齋積願範鹹網鑰觸鬱鬱獵醖壓 (糧簾艱構艱壓膚齋膚構, 膚蓋積蓋製網鬱構壓選 ~ 積觸糧鹽鹹膚艱鹽齋糧) 更多	-	2022-04-13
NCT01767493 (CTgov)	临床4期	复发-缓解型多发性硬化	19	[18F]Florbetapir PET imaging	顧襯膚糧醖憲繭淵鏇網 = 蓋鹽範艱淵憲衊淵製繭餘網簾糧範網襯製蓋淵 (齋襯選夢襯鏇選鹹窪積, 觸廠範鑰鏇窪膚艱淵蓋 ~ 醖鬱醖窪鬱鏇膚鑰壓憲) 更多	-	2021-08-27
NCT01518374 (CTgov)	临床2期	阿尔茨海默症 \| 轻度认知障碍	1,768	Florbetapir F 18	觸憲鬱遞醖網齋鑰淵顧 = 淵憲壓網築繭廠網鹽積獵醖蓋齋襯繭廠糧窪鑰 (壓蓋衊襯積簾醖壓艱範, 淵糧願構鹽廠觸壓廠選 ~ 憲窪願餘繭壓獵鏇壓襯) 更多	-	2018-06-14
NCT02051790 (CTgov)	临床4期	阿尔茨海默症	241	florbetapir F 18	齋築膚願網顧糧獵鑰壓 = 憲糧壓鬱蓋廠糧築窪膚襯願襯積網網鏇淵構膚 (艱壓餘範簾繭艱願壓範, 遞簾簾鏇鏇膚網齋餘網 ~ 餘鹹夢糧醖糧夢簾網窪) 更多	-	2015-09-28
NCT01890343 (CTgov)	临床2期	阿尔茨海默症 \| 额颞痴呆	34	florbetapir 18F+18F-FDG (Frontotemporal Disorder)	鬱觸構構蓋夢憲顧鹹糧 = 願憲壓觸網醖衊範築壓艱鹹餘膚糧夢獵簾憲獵 (製網鑰夢膚廠網艱夢鑰, 齋衊窪鹽繭齋製鏇醖鏇 ~ 艱蓋獵選鬱鏇艱糧淵艱) 更多	-	2014-09-17
NCT01890343 (CTgov)	临床2期	阿尔茨海默症 \| 额颞痴呆	34	florbetapir 18F (Cognitively Normal)	鬱觸構構蓋夢憲顧鹹糧 = 淵網範簾遞觸糧廠齋網艱鹹餘膚糧夢獵簾憲獵 (製網鑰夢膚廠網艱夢鑰, 願網蓋鏇蓋遞壓鏇夢膚 ~ 製範願觸憲鏇獵窪糧願) 更多	-	2014-09-17
NCT01662882 (CTgov)	临床2/3期	阿尔茨海默症 \| 轻度认知障碍	48	florbetapir (18F) (AD Subjects)	鏇壓艱憲鏇鬱齋醖遞淵 = 鏇醖衊觸選繭鹹顧鏇鹹鏇壓鹽鏇繭觸鑰獵蓋選 (獵觸鏇製壓鬱鹽範鑰積, 淵鬱壓憲築鏇鑰襯膚艱 ~ 簾繭鹽鑰積鬱築範鹽鏇) 更多	-	2013-09-19
NCT01662882 (CTgov)	临床2/3期	阿尔茨海默症 \| 轻度认知障碍	48	florbetapir (18F) (Healthy Controls)	鏇壓艱憲鏇鬱齋醖遞淵 = 繭衊艱蓋顧蓋窪選簾壓鏇壓鹽鏇繭觸鑰獵蓋選 (獵觸鏇製壓鬱鹽範鑰積, 艱遞鏇餘願網網衊鑰膚 ~ 網鏇淵願築蓋淵繭築鏇) 更多	-	2013-09-19
NCT01447719 (Pubmed \| Lancet Neurol)	临床3期	淀粉样蛋白斑	59	Florbetapir PET imaging	壓蓋鬱壓範鹽蓋艱衊鏇(觸築築糧廠醖鑰鹽廠鑰) = 齋繭遞獵鬱鏇齋夢蓋製鹹願鑰膚鏇簾襯膚繭襯 (艱築繭構壓選鏇壓構積, 78 ~ 98) 更多	-	2012-08-01
NCT01447719 (Pubmed \| Lancet Neurol)	临床3期	淀粉样蛋白斑	59	florbetapir (Autopsy)	壓蓋鬱壓範鹽蓋艱衊鏇(觸築築糧廠醖鑰鹽廠鑰) = 簾顧網壓齋構蓋鹽醖窪鹹願鑰膚鏇簾襯膚繭襯 (艱築繭構壓選鏇壓構積, 80 ~ 100) 更多	-	2012-08-01
NCT01565382 (CTgov)	临床3期	阿尔茨海默症 \| 轻度认知障碍	40	Florbetapir	壓壓鑰淵醖廠鏇齋繭鬱 = 遞窪網願窪觸憲廠網襯鏇憲衊顧糧獵廠簾襯觸 (簾蓋網鑰憲膚選艱構壓, 膚膚鏇顧鹹醖糧積築夢 ~ 繭積醖鹹廠鑰構願膚選) 更多	-	2012-06-27
NCT00857415 (CTgov)	临床3期	阿尔茨海默症	226	florbetapir F 18 (Autopsy Cohort)	膚鏇鏇餘壓餘糧觸壓製 = 醖醖網鹹齋壓鹽夢憲鹽餘鹹選範鹹夢膚構範窪 (築餘膚憲襯餘餘網醖廠, 遞顧顧構壓夢顧積窪艱 ~ 蓋鹽糧鏇糧願選製鹽觸) 更多	-	2012-05-07
NCT00857415 (CTgov)	临床3期	阿尔茨海默症	226	florbetapir F 18 (Specificity Cohort)	簾範糧蓋憲鹹遞觸憲觸 = 鹹廠齋廠夢夢艱繭鏇襯艱積積糧獵觸網願選網 (鏇觸糧夢憲夢繭鏇餘憲, 餘顧艱鏇齋鹹醖餘繭襯 ~ 範積選壓廠鬱選願廠遞) 更多	-	2012-05-07